Innovus Pharmaceuticals Inc., an expanding commercial-stage medication company that provides over-the-counter products for both men and women, will be filing a product licence application (PLA) in Canada for its drug, Xyralid.
The drug is a "fast-acting and powerful" lidocaine-based anesthetic cream that is used to relieve pain and symptoms that are brought on by hemorrhoids, Business Wire reported. If the license is accepted by Health Canada, Xyralid will be available for sale both over-the-counter and by prescription. The product will be targeting the over 1.2 million Canadian patients who suffer from hemorrhoids, which are swollen veins in the anus and lower rectum oftentimes brought on by straining.
“We are very excited about filing the PLA for our Xyralid drug in Canada,” Dr. Bassam Damaj, the president and CEO of Innovus Pharma, said. “If approved by Health Canada, Xyralid will be our fourth product on the Canadian market including Zestra, Zestra Glide and Uxor (EjectDelay) marketed by Orimed Pharma.”
On May 18, San Diego-based Innovus Pharmaceuticals announced its filing of a PLA to market Vesele, its popular sexual dysfunction product, with Health Canada.